Positive results for ECLS trial presented at the World Conference for Lung Cancer in Barcelona

Past event

Date

09 September 2019

Location

Barcelona, Spain

View map

The findings, presented at the 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, are an important validation of Oncimmune's diagnostic platform technology which harnesses the power of the immune system, to detect evidence of the body's natural response to cancer. The technology can detect cancer on average four years before standard clinical diagnosis.

These landmark findings are likely to have globally significant implications for the early detection of lung cancer by showing how a simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher.

Professor Frank Sullivan, Chief Investigator on ECLS trial